^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NX-1607
i
Other names: NX-1607, NX1607, NX 1607
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nurix Therap
Drug class:
T-cell stimulant, CBLB expression inhibitor
Related drugs:
12ms
NX-1607-101: A Study of NX-1607 in Adults With Advanced Malignancies (clinicaltrials.gov)
P1, N=345, Recruiting, Nurix Therapeutics, Inc. | Phase classification: P1b --> P1 | Trial completion date: Feb 2025 --> Feb 2026
Phase classification • Trial completion date • Metastases
|
paclitaxel • oxaliplatin • irinotecan • NX-1607
over1year
NX-1607-101: A Study of NX-1607 in Adults With Advanced Malignancies (clinicaltrials.gov)
P1b, N=363, Recruiting, Nurix Therapeutics, Inc. | N=268 --> 363
Enrollment change • Metastases
|
paclitaxel • NX-1607
over2years
A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES (EHA 2022)
Immunomodulatory drugs (IMiDs, e.g., lenalidomide) are approved as monotherapy for follicular lymphoma (FL), MZL, and MCL, in combination with other therapies for diffuse large B-cell lymphoma (DLBCL) and have shown synergy with BTK-targeted therapy...NX-2127 was shown to degrade both wild-type (WT) and C481-mutated (ibrutinib-resistant) BTK protein in vitro...The primary endpoint are dose-limiting toxicities and maximum tolerated dose (Phase 1a), objective response (Phase 1b), and safety (Phase 1a and Phase 1b) of NX-1607...Conclusion Accrual is ongoing. Clinical trial information: NCT04830137.
Clinical • P1 data
|
IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
|
BTK C481S • BTK mutation • BTK C481
|
Imbruvica (ibrutinib) • lenalidomide • zelebrudomide (NX-2127) • NX-1607
Share via
